CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

The Lancet Oncology

Volumn 12, Issue 11, 2011, Pages 1013-1022

  Pfreundschuh, Michael ^a   Kuhnt, Evelyn ^b   Trümper, Lorenz ^c   Österborg, Anders ^d   Trneny, Marek ^e   Shepherd, Lois ^f   Gill, Devinder S ^g   Walewski, Jan ^h   Pettengell, Ruth ⁱ   Jaeger, Ulrich ^j   Zinzani, Pier Luigi ^k   Shpilberg, Ofer ^l   Kvaloy, Stein ^m   de Nully Brown, Peter ⁿ   Stahel, Rolf ^o   Milpied, Noel ^p   López Guillermo, Armando ^q   Poeschel, Viola ^a   Grass, Sandra ^a   Loeffler, Markus ^b   Murawski, Niels ^a   more..

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e CHARLES UNIVERSITY   (Czech Republic)

^f QUEEN S UNIVERSITY   (Canada)

^g PRINCESS ALEXANDRA HOSPITAL   (Australia)

^h INSTITUTE OF ONCOLOGY   (Poland)

ⁱ ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^j UNIVERSITY HOSPITAL GRAZ   (Austria)

^k Istituto di Ematologia L e A Seragnoli   (Italy)

^l RABIN MEDICAL CENTER   (Israel)

^m OSLO UNIVERSITY HOSPITAL   (Norway)

ⁿ University of Copenhagen   (Denmark)

^o UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^p HAUT LÉVÊQUE HOSPITAL   (France)

^q H Clinic i Provincial   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ALGORITHM; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMPUTER AIDED DESIGN; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; EVENT FREE SURVIVAL; HUMAN; INTENTION TO TREAT ANALYSIS; LARGE CELL LYMPHOMA; LONG TERM CARE; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION;

ADOLESCENT; ADULT; AGE FACTORS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRALIA; CANADA; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; EUROPE; HUMANS; ISRAEL; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 80053384016     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70235-2     Document Type: Article

References (18)

1. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993, 329:987-994. The International Non-Hodgkin's Lymphoma Prognostic Factors Project.
2. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
3. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:3121-3127.
4. Pfreundschuh M, Trümper L, Österborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7:379-391. for the MabThera International Trial (MInT) Group.
5. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17:3835-3849.
6. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989, 7:1630-1636.
7. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999, 17:1244-1253.
8. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010, 116:2040-2045.
9. Schmitz N, Nickelsen M, Ziepert M, et al. Aggressive chemotherapy (CHOEP-14) and rituximab or high-dose therapy (MegaCHOEP) and rituximab for young high-risk patients with aggressive B-cell lymphoma: results of the MegaCHOEP trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009, 114:168s.
10. Récher C, Coiffier B, Haioun C, et al, for the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Randomised phase 3 study (LNH03-2B) of intensified chemotherapy ACVBP plus rituximab versus standard CHOP plus rituximab for young patients with diffuse large-B-cell lymphoma. Lancet (in press).
11. Tarella C, Passera R, Magni M, et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 2011, 29:814-824.
12. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008, 9:105-116. for the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
13. Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 2008, 26:2258-2263.
14. Gang AO, Strom C, Pedersen M, et al. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. Ann Oncol 2011, published online April 2. 10.1093/annonc/mdr058.
15. Milpied N-J, Legouill S, Lamy T, et al. No benefit of rituximab (R)-high dose therapy (R-HDT) over R-CHOP14 for young adults with diffuse large B-cell lymphoma: preliminary results of the GOELAMS 075 prospective multicentre randomized trial. Blood 2010, 116:301.
16. Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 2008, 9:435-444. for the MabThera International Trial (MInT) Group.
17. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004, 104:626-633.
18. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004, 104:634-641.